KALA BIO Halts Eye Drug Development After Trial Failure
KALA BIO’s lead drug, KPI-012, failed its Phase 2b trial for Persistent Corneal Epithelial Defect (PCED), prompting the company to stop development and pursue cash-saving strategic options.
NOTRELOAD AI
Larimar Stock Plummets: Anaphylaxis Events in Drug Study
Larimar's experimental drug for Friedreich's ataxia, nomlabofusp, showed positive biological results and improved clinical trends, but safety concerns over seven cases of anaphylaxis caused the stock to drop dramatically.
IO Biotech Restructuring After Cylembio BLA Rejection
IO Biotech won't submit its Cylembio cancer vaccine application after the FDA recommended against it due to trial results narrowly missing significance. IOBT will plan a new study and cut 50% of staff to save cash.
Electronic Arts Acquired for $55 Billion in Largest Leveraged Buyout on Record
Electronic Arts is going private in a $55 billion ($210 per share in cash) transaction, the largest leveraged buyout on record, driven by an investor consortium including PIF, Silver Lake, and Affinity Partners.
TSMC Rejects Intel Investment and Partnership Rumors
Top chipmaker TSMC denied rumors of an investment or partnership with struggling Intel. TSMC stated it has not entered talks for joint ventures or technology transfer.
Enanta Stock Drops After Mixed Results from RSV Drug Trial
Enanta Pharmaceuticals' experimental RSV drug caused stock market disappointment after failing its main goal (reducing symptom time). However, the trial showed success in important secondary areas, like clearing the virus faster.